161 related articles for article (PubMed ID: 38533502)
1. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.
Temizoz B; Shibahara T; Hioki K; Hayashi T; Kobiyama K; Lee MSJ; Surucu N; Sag E; Kumanogoh A; Yamamoto M; Gursel M; Ozen S; Kuroda E; Coban C; Ishii KJ
Front Immunol; 2024; 15():1353336. PubMed ID: 38533502
[TBL] [Abstract][Full Text] [Related]
2. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Conlon J; Burdette DL; Sharma S; Bhat N; Thompson M; Jiang Z; Rathinam VA; Monks B; Jin T; Xiao TS; Vogel SN; Vance RE; Fitzgerald KA
J Immunol; 2013 May; 190(10):5216-25. PubMed ID: 23585680
[TBL] [Abstract][Full Text] [Related]
3. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation.
Xiao Z; Cui X; Liu F; Wang Y; Liu X; Zhou W; Zhang Y
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167149. PubMed ID: 38565383
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA.
Chang J; Hou S; Yan X; Li W; Xiao J
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049669
[TBL] [Abstract][Full Text] [Related]
5. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential.
Prantner D; Perkins DJ; Lai W; Williams MS; Sharma S; Fitzgerald KA; Vogel SN
J Biol Chem; 2012 Nov; 287(47):39776-88. PubMed ID: 23027866
[TBL] [Abstract][Full Text] [Related]
6. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
Downey CM; Aghaei M; Schwendener RA; Jirik FR
PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
[TBL] [Abstract][Full Text] [Related]
7. The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease.
Cerón S; North BJ; Taylor SA; Leib DA
Virology; 2019 Mar; 529():23-28. PubMed ID: 30648635
[TBL] [Abstract][Full Text] [Related]
8. Integrative Strategy for Investigating the Interactions between STING and Small-Molecule Ligands.
Xu Y; Li W; Zhou X; Gao Y; Ding L; Xu L; Mao X; Zhou A; Wang X; Ning X
Langmuir; 2022 Nov; 38(46):14185-14191. PubMed ID: 36354159
[TBL] [Abstract][Full Text] [Related]
9. Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.
Synn CB; Kim DK; Kim JH; Byeon Y; Kim YS; Yun MR; Lee JM; Lee W; Lee EJ; Lee S; Lee YW; Lee DJ; Kim HW; Kim CG; Hong MH; Park JD; Lim SM; Pyo KH
Yonsei Med J; 2022 Jan; 63(1):42-55. PubMed ID: 34913283
[TBL] [Abstract][Full Text] [Related]
10. Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome.
Papinska J; Bagavant H; Gmyrek GB; Sroka M; Tummala S; Fitzgerald KA; Deshmukh US
J Dent Res; 2018 Jul; 97(8):893-900. PubMed ID: 29505322
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists.
Hwang J; Kang T; Lee J; Choi BS; Han S
Org Biomol Chem; 2019 Feb; 17(7):1869-1874. PubMed ID: 30117503
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary Involvement in a Mouse Model of Sjögren's Syndrome Induced by STING Activation.
Papinska J; Bagavant H; Gmyrek GB; Deshmukh US
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630417
[TBL] [Abstract][Full Text] [Related]
13. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA.
Gao P; Zillinger T; Wang W; Ascano M; Dai P; Hartmann G; Tuschl T; Deng L; Barchet W; Patel DJ
Cell Rep; 2014 Sep; 8(6):1668-1676. PubMed ID: 25199835
[TBL] [Abstract][Full Text] [Related]
14. Identification of α-Mangostin as an Agonist of Human STING.
Zhang Y; Sun Z; Pei J; Luo Q; Zeng X; Li Q; Yang Z; Quan J
ChemMedChem; 2018 Oct; 13(19):2057-2064. PubMed ID: 30079976
[TBL] [Abstract][Full Text] [Related]
15. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
16. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
17. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
Philpott M; Ching LM; Baguley BC
Eur J Cancer; 2001 Oct; 37(15):1930-7. PubMed ID: 11576850
[TBL] [Abstract][Full Text] [Related]
18. Anticancer flavonoids are mouse-selective STING agonists.
Kim S; Li L; Maliga Z; Yin Q; Wu H; Mitchison TJ
ACS Chem Biol; 2013 Jul; 8(7):1396-401. PubMed ID: 23683494
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA.
Shih AY; Damm-Ganamet KL; Mirzadegan T
Biophys J; 2018 Jan; 114(1):32-39. PubMed ID: 29320694
[TBL] [Abstract][Full Text] [Related]
20. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
